CORC

浏览/检索结果: 共3条,第1-3条 帮助

限定条件                    
已选(0)清除 条数/页:   排序方式:
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. 期刊论文
JAMA oncology, 2018, 卷号: 4, 页码: 1569-1575
作者:  Han Baohui;  Li Kai;  Wang Qiming;  Zhang Li;  Shi Jianhua
收藏  |  浏览/下载:5/0  |  提交时间:2019/11/26
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment 期刊论文
CANCER BIOLOGY & MEDICINE, 2018, 卷号: 15, 页码: 443-451
作者:  Wang, Jing;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载:5/0  |  提交时间:2019/11/26
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer 期刊论文
LUNG CANCER, 2018, 卷号: 122, 页码: 32-37
作者:  Si, Xiaoyan;  Zhang, Li;  Wang, Hanping;  Zhang, Xiaotong;  Wang, Mengzhao
收藏  |  浏览/下载:3/0  |  提交时间:2019/11/26


©版权所有 ©2017 CSpace - Powered by CSpace